Cavosonstat

DRUG4 trials

Sponsors

Nivalis Therapeutics, Inc., University of North Carolina, Chapel Hill

Conditions

AsthmaCystic Fibrosis

Phase 1

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

CompletedNCT02934139

Nivalis Therapeutics, Inc.Cystic Fibrosis

Start: 2016-10-31End: 2017-01-31Updated: 2017-01-31

Phase 2

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

CompletedNCT02589236

Nivalis Therapeutics, Inc.Cystic Fibrosis

Start: 2015-11-30End: 2016-12-31Updated: 2017-01-10

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

Nivalis Therapeutics, Inc.Cystic Fibrosis

Start: 2016-04-30End: 2017-04-30Updated: 2016-11-21

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

CompletedNCT04129931

University of North Carolina, Chapel HillAsthma

Start: 2019-12-19End: 2025-03-19Updated: 2026-04-01

Related Papers

Symptom-driven inhaled corticosteroid/long-acting beta-agonist therapy for adult patients with asthma who are non-adherent to daily maintenance inhalers: a study protocol for a pragmatic randomized controlled trial.

2022-12-054 citations

Air quality, Environment and Respiratory Outcomes in Bronchopulmonary Dysplasia, the AERO-BPD cohort study: design and adaptation during the SARS-CoV-2 pandemic

BMJ Open Respiratory Research2021-06-0112 citations